Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE-HD: Pridopidine in Huntington's Disease
NCT07609108Phase 3Recruiting
- Sponsor
- Prilenia Therapeutics
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Countries
- 12
01
Overview
A Phase 3 trial of pridopidine in Huntington's disease (HD), sponsored by Prilenia Therapeutics. Started Jul 2026; status: recruiting.
02
Drugs
pridopidine
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT07609108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07609108.